Stoeckel K, Trueb V, Dubach U C, Heintz R C, Ascalone V, Forgo I, Hennes U
Br J Clin Pharmacol. 1985 Feb;19(2):249-54. doi: 10.1111/j.1365-2125.1985.tb02638.x.
The pharmacokinetics of glibornuride (25 mg i.v.) and the accompanying insulin and glucose responses were characterized in eight human subjects in the presence and absence of steady-state tenoxicam (20 mg p.o./day for 2 weeks). Tenoxicam affected neither the pharmacokinetic parameters of glibornuride (systemic clearance, volume of distribution and biological half-life) nor the responses of plasma insulin and blood glucose to glibornuride. The single i.v. dose of glibornuride had no detectable effect on the kinetics of tenoxicam.
在8名人类受试者中,研究了在存在和不存在稳态替诺昔康(每天口服20mg,持续2周)的情况下,格列本脲(静脉注射25mg)的药代动力学以及伴随的胰岛素和葡萄糖反应。替诺昔康既不影响格列本脲的药代动力学参数(全身清除率、分布容积和生物半衰期),也不影响血浆胰岛素和血糖对格列本脲的反应。单次静脉注射格列本脲对替诺昔康的动力学没有可检测到的影响。